Market Snapshot and Strategic Outlook for Qingdao Haier Biomedical Co. Ltd.
During the 24‑hour trading window that closed at 05:23 PM Central Europe on Friday 23 September, Qingdao Haier Biomedical Co. Ltd. (688139.SS) exhibited a flat price movement, holding steady at CNY 33.80 on the major exchanges. The shares are presently available at a liquidity level of approximately 323.8 million units, translating into a market capitalization of roughly CNY 10.2 billion. In the preceding day, a volume of CNY 96.5 million was exchanged, a figure that underscores the moderate trading activity for the stock.
Notably, the share price has declined 9.92 % since the close of the prior month, reflecting a broader trend of market volatility. The simple moving average (SMA) over the past 200 trading days sits at CNY 29.71, while the 52‑week high and low were CNY 38.80 (14 January 2026) and CNY 24.40 (29 June 2026), respectively.
Financial Highlights – Third Quarter 2026
Qingdao Haier Biomedical has announced that its third‑quarter revenue grew, and its adjusted net profit increased, signalling a sustained expansion across several business lines. The company attributes this performance to:
- Pharmaceutical Segment – An upsurge in orders from leading domestic and international pharmaceutical customers.
- Overseas Operations – Continued penetration in foreign markets, supported by strategic partnerships and localized supply chains.
- Emerging‑Industry Focus – Expansion into low‑temperature storage solutions, which have broadened the product mix and improved margin profiles.
Management expressed confidence that full‑year revenue growth will marginally surpass the 10 % target set earlier in the fiscal year. The emphasis on low‑temperature storage is expected to sustain the company’s profitability trajectory and reinforce its long‑term growth outlook.
Peer Performance – 24‑Hour View
| Symbol | Trading Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|
| Xiamen Port Development (000905.SZ) | 0 % | CNH 8.35 | CNH 13.2 bn | 27.29 |
| Siglent Lt (688112.SS) | 0 % | CNY 73.9 | CNY 12.3 bn | 78.89 |
| Changzhou Fusion New Mater (688503.SS) | 0 % | CNY 50.6 | CNY 12.2 bn | – |
| Shanghai Awinic (688798.SS) | 0 % | CNY 54.49 | CNY 12.2 bn | 44.94 |
| Zhongan Online P&C Insuran‑h (6060.HK) | –2.67 % | HKD 9.2 | HKD 14.4 bn | 6.62 |
While Qingdao Haier Biomedical’s share price remained unchanged, its peers largely exhibited similar stability, with the exception of Zhongan Online P&C Insuran‑h, which experienced a modest decline.
Company Profile
Qingdao Haier Biomedical Co. Ltd., headquartered in Qingdao, China, specializes in the development and production of high‑quality biomedical products and services. The firm has a pronounced focus on reproductive health and fertility technologies, positioning itself as a key player in the rapidly evolving biopharmaceutical landscape.
Conclusion
Qingdao Haier Biomedical’s recent earnings release highlights a resilient operational model, bolstered by diversified revenue streams and a clear strategic emphasis on low‑temperature storage solutions. Despite a modest share‑price decline relative to the prior month, the company’s robust quarterly performance and forward‑looking guidance suggest a favourable trajectory for investors who prioritize steady growth within the biotechnology sector.